Pharmacol Rev June 2002 PMID 12037135

International Union of Pharmacology. XXVII. Classification of cannabinoid receptors.

A C Howlett, F Barth, T I Bonner, G Cabral, P Casellas, W A Devane, C C Felder, M Herkenham, K Mackie, B R Martin, R Mechoulam, R G Pertwee

Download social card

Mentions

Peak: 2 in Oct 2022

across 3 sources since Jun 2020

Extended reach

422,085

potential audience

Total likes

3,459

Video views

420,434

Mentions per month

Jun 2020 – Jan 2024

Where it's discussed

X / Twitter2 posts
YouTube2 videos
News2 articles

AI synopsis

What people are saying

The overall tone reflects mild skepticism and curiosity, exemplified by comments like shifts in enzyme processing and neurogenesis improvements, using phrases such as 'Why not promote' or referencing potential benefits for Alzheimer's, which signals tentative engagement and interest but no strong consensus or deep impact perceived.

AgreementLow agreement

Most discussions seem skeptical or dismissive about the relevance or implications of the publication, especially with remarks questioning the practical benefits, such as 'Why not promote a shift'.

InterestModerate interest

The posts show moderate interest, focusing on specific biochemical processes like gamma-secretase activity and its relation to neurological functions, indicating curiosity but not deep engagement.

EngagementNeutral engagement

The conversations are somewhat superficial, mainly linking to broader issues like Alzheimer's disease and neurogenesis without detailed analysis of the classification of cannabinoid receptors.

ImpactNeutral impact

The discussions suggest limited perception of immediate impact, mostly exploring theoretical or potential implications rather than concrete applications or significant breakthroughs.

Abstract in brief

Two main types of cannabinoid receptors have been identified: CB1, primarily found in the central nervous system, and CB2, mostly located on immune cells, with both sharing significant amino acid sequence similarity but differing in signaling and tissue distribution.
CB1 receptors are involved in inhibiting neurotransmitter release in neurons and are coupled to G proteins that regulate various ion channels and enzymes, while CB2 receptors influence immune responses and cytokine release.
Endogenous compounds like arachidonoylethanolamide and 2-arachidonoylglycerol activate these receptors, but it's uncertain if they are the only natural ligands, and research is ongoing to discover additional receptor types or ligands.

Read the full abstract

All mentions

Understanding THC and Its Impact on the Nervous System

THC is the main psychoactive component of cannabis and affects the nervous system by acting as a partial agonist at CB1 receptors, causing intoxication and therapeutic effects. It remains controversial due to potential…

Neuroscientifically Challenged · Jun 10, 2020 420,417 views

Understanding THC: Psychoactive Compound in Cannabis and Its Effects

THC is the main psychoactive component of cannabis, affecting the brain by binding to CB1 receptors. Its effects include euphoria, sedation, increased appetite, and impaired cognition. This video explains THC's role and…

Kind Cannabis · Jan 2, 2024 17 views

turizemptuj

@turizemptuj · X

RT @turizemptuj: @KarlHerrup @_keliu_ @amangalmurti Why not promote a shift in γ-secretase substrate processing to favor processing of Notc…

Oct 5, 2022 · 1 share · 814 followers View post →

turizemptuj

@turizemptuj · X

Oct 5, 2022 · 1 share · 814 followers View post →

Lack of Tolerance to Δ9-Tetrahydrocannabinol in Chimpanzees ...

News

https://doi.org/10.1124/pr.54.2.161 · Crossref. Neil T. Smith,. A review of the published literature into cannabis withdrawal symptoms in human users, Addiction ...

Dec 16, 2025 View →

What is Cannabinol (CBN)? More About the “Sleepy” Cannabinoid ...